Subjects who receive the Treovance stent-graft for Abdominal Aortic Aneurysm

Phase 2
Waitlist Available
Led By Matthew Eagleton, MD
Research Sponsored by Bolton Medical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement
Be older than 18 years old
Must not have
Be younger than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up12 months
Awards & highlights
No Placebo-Only Group

Study Summary

This trial is testing a new stent-graft for people with abdominal aortic aneurysms. They want to see if it's safe and effective.

Eligible Conditions
  • Abdominal Aortic Aneurysm

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Efficacy
Primary Safety
Secondary outcome measures
Secondary Efficacy Endpoint -- Device-Related Complications
Secondary Efficacy Endpoint-- Secondary interventions
Secondary Safety Endpoint

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreovanceExperimental Treatment1 Intervention
Subjects who receive the Treovance stent-graft

Find a site

Who is running the clinical trial?

Bolton MedicalLead Sponsor
15 Previous Clinical Trials
2,476 Total Patients Enrolled
Matthew Eagleton, MDPrincipal Investigator
Cleveland Clinic Foundaton
1 Previous Clinical Trials
143 Total Patients Enrolled

Media Library

Treovance Stent-Graft (Stent-Graft) Clinical Trial Eligibility Overview. Trial Name: NCT02009644 — Phase 2
Abdominal Aortic Aneurysm Research Study Groups: Treovance
Abdominal Aortic Aneurysm Clinical Trial 2023: Treovance Stent-Graft Highlights & Side Effects. Trial Name: NCT02009644 — Phase 2
Treovance Stent-Graft (Stent-Graft) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02009644 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Will this research be conducted with elderly participants?

"Eligibility for this particular clinical trial is restricted to patients that are between 18 and 85 years old. In contrast, there are 8 trials that are only enrolling patients below the age of eighteen and 158 studies recruiting participants above 65."

Answered by AI

At how many locations is this research being conducted?

"The trial is based in University of Iowa Hospital and Clinic, situated in Iowa City, with other locations in University of Alabama-Birmingham, Birmingham, Arizona Heart Institute in Phoenix as well as 32 other sites."

Answered by AI

Are there any more spots left for people who want to participate in this research project?

"From the information on, it can be gathered that this trial is not presently looking for patients. This trial was initially posted on 11/23/2013 and was last updated on 6/25/2020; however, there are 160 other trials enrolling patients at this time."

Answered by AI

Could I qualify to be a subject in this clinical trial?

"Aneurysm patients who are between 18 and 85 years old may be eligible for this study. Up to 150 people can participate."

Answered by AI

Does the Treovance stent-graft have FDA approval for use in human subjects?

"This is a Phase 2 trial, which means that while there are safety data, there are no efficacy data. Therefore, the Power team gave it a rating of 2."

Answered by AI
~14 spots leftby Sep 2024